Table 1 Summary of clinical studies assessing infectious disease mRNA vaccines.

From: The promise of mRNA vaccines: a biotech and industrial perspective

Disease targetStudy stagemRNADelivery formulationTrial citationStatusOrganizationRef.
RSVPh1mRNA-1172Merck proprietary formulationNot knownOngoingMerck/Moderna70
RabiesPh1RG-SAM [CNE]Cationic lipid formulationNCT04062669OngoingGSKhttps://clinicaltrials.gov/ct2/show/NCT04062669
Chikungunya virusPh1mRNA-1388Not disclosedNot knownOngoing (interim results)Moderna71
RabiesPh1CV7202LNPNCT03713086Ongoing (interim results)Curevac72
Human metapneumovirus (hMPV) and parainfluenza type 3 (PIV3)Ph1mRNA-1653LNPNCT03392389Ongoing (interim results)Moderna73
Influenza (H10N8)Ph1mRNA-1440LNPNCT03076385Ongoing (interim results)Moderna63
Influenza (H7N9)Ph1mRNA-1851LNPNCT03345043Ongoing (interim results)Moderna63
Cytomegalovirus (CMV); six valencies expressing a pentamer and gBPh1mRNA-1647 mRNA-1443LNPNCT03382405Ongoing (interim results for mRNA-1647)Moderna74
Zika virusPh1mRNA-1893LNPNCT04064905OngoingModerna75
Zika virusPh1mRNA-1325Not disclosedNCT03014089CompletedModerna76
Rabies virusPh1CV7201ProtamineNCT02241135CompletedCurevac69
RSVPh1mRNA-1777Not disclosedNot knownCompleted (not yet reported)Merck/Moderna68